Functionalized Nanotube Therapeutic Compositions

SK1175

Summary of Invention

Single wall nanotubes (SWNT) are inert, stable, flexible, non-toxic and non-immunogenic. They can be functionalized, that is, covalently bonded units can be added, making them soluble, and allowing them to carry targeting and therapeutic moieties. This invention is a method of treating a disease by administering soluble SWNTs functionalized with targeting moieties and payload molecules. The payload is delivered through the targeting moiety to the diseased cells where the payload has a therapeutic effect against the cells or elicits a therapeutic effect from the cells thereby treating the disease.

This invention discloses methods (1) to diagnose or locate a cancer, (2) to treat a cancer, or to elicit an immune response against a cancer or (3) to deliver an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT.

Advantages

  • Soluble, non-toxic, non-immunogenic therapeutic and diagnostic constructs
  • Enormous flexibility for key variables: targeting elements, payloads, solubility, other physical properties
  • Disease-specific
  • Many possible therapeutic routes

Area of Application

Therapeutic, diagnostic

Stage of Development

Animal studies

Lead Inventor

David Scheinberg, MD, PhD, Program Chair and Laboratory Head, Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering

Patent Information

U.S. National Patent 8,540,965 issued September 24, 2013

References

Escorcia FE, et al. (2007) Nanomed. Dec;2(6):805-15

Contact Information

Yashodhara Dash, MBBS, PhD, MBA
Senior Manager, Technology Management and Commercialization
Tel: 646-888-1073
E-mail: dashy@mskcc.org
Stage of Development
Animal studies
Indications